Archive: Company News

Company News: MediGene Reports Financial Results for the Fiscal Year 2009 and Announces New CFO

MediGene AG today reported the results for its fiscal year 2009 and an outlook for 2010. Moreover, the company announced that its Chief Financial Officer Dr. Thomas Klaue will resign from office after the Annual Shareholders’ Meeting on May 11, 2010. He will be succeeded by Arnd Christ, formerly CFO of Swiss-based biotech company NovImmune. For further details, please click here.

Company News: Affectis Pharmaceuticals Raises €3.3M in Financing and Names Alex Martin Chief Executive Officer

Affectis Pharmaceuticals AG today announced it has raised €3.3M in the first tranche of a Series D financing. Existing investors LSP, Aescap Venture, KfW, Bayernkapital and EMBL Ventures were participating in the round. Moreover, the company announced the appointment of Alex Martin as Chief Executive Officer. Mr. Martin had previously served on the Supervisory Board of Affectis and joined the company fulltime as CFO in August of 2009. He succeeds founding CEO Herbert Stadler, who is retiring.

Mr. Martin brings over 20 years experience in the pharmaceutical industry, including roles at Novartis, where he was Vice President, Global Business Development & Licensing, and SmithKline Beecham where he held positions of increasing responsibility in sales, marketing, and business development. Immediately prior to Affectis Mr. Martin served as COO of Intercept Pharmaceuticals based in New York.

The full announcement is available at Affectis’  website.

Company News: Micromet Closes $80.5 Million Public Offering of Common Stock

Micromet, Inc. (NASDAQ: MITI) announced today the closing of its previously announced underwritten public offering and raises net proceeds of approximately $ 75.3 million, after deducting the underwriting discount and estimated offering expenses. For more information, please click here.

Company News: Micromet Reports Fourth Quarter and Full Year 2009 Financial Results

Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009.  The Company also highlighted recent pipeline progress and outlined expected 2010 milestones.

Further details can be found at: www.micromet-inc.com

1 … 169 170 171